Motilal Oswal's research report on Persistent Systems
Persistent Systems (PSYS) delivered 3QFY24 revenue of USD300.6m, up 3.1% QoQ in CC terms, in line with our estimate. Deal win TCV was at a record high (USD 521m), aided by strong wins and renewals in North America. EBITDA margin at 17.7% (up 90bp QoQ) beat our estimates; the improvement was attributed to seasonality in IP business and SG&A optimization. PSYS’s 3QFY24 revenue performance was positive, although the growth was skewed toward Healthcare and Life (up 16% QoQ); the other two verticals reported muted growth. Despite a seasonal furlough, the deal TCV recorded yet another quarter of strong growth, up 8.8% QoQ (vs +26% QoQ in 2Q), translating to 1.7x BTB.
Outlook
We believe PSYS’ valuation appropriately factors in the favorable growth along with the adverse macro environment. We value the stock at 37x FY26E EPS. We reiterate Neutral as we see limited upside from the current levels.
For all recommendations report, click here
Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
Find the best of Al News in one place, specially curated for you every weekend.
Stay on top of the latest tech trends and biggest startup news.
